A Blank Rome team represented iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, in connection with the closing of an underwritten public offering of its securities for initial gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses.
In addition, if all of the warrants sold by iBio in the offering are exercised in full for cash, iBio would receive additional gross proceeds of $50 million for total gross proceeds of approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. The offering closed on August 22, 2025.
iBio intends to use the net proceeds from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, the myostatin and activin A bispecific, and IBIO-600 programs, through key development milestones, as well as to continue to progress its other preclinical pipeline assets, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes.
For more information about this offering, please read the press release: iBio Announces Closing of $50 Million Public Offering (August 25, 2025).
The Blank Rome team was led by Leslie Marlow, Melissa Palat Murawsky and Jamie L. Plisner, with assistance from Brad L. Shiffman, Joseph T. Gulant, Thomas E. Carroll, Alyson Bright, and Christy Grzan.
